Cargando…
Improvement in Plasma Drug Activity during the Early Treatment Interval among Tanzanian Patients with Multidrug-Resistant Tuberculosis
BACKGROUND: Individual pharmacokinetic variability may be common in patients treated for multidrug-resistant tuberculosis (MDR-TB) but data are sparse from resource-limited settings and across the early treatment interval. METHODS: Plasma drug activity, as measured by the TB Drug Activity (TDA) assa...
Autores principales: | Ndusilo, Norah D., Heysell, Scott K., Mpagama, Stellah G., Gratz, Jean, Segesela, Farida H., Pazia, Saumu J., Wang, Xin-Qun, Houpt, Eric R., Kibiki, Gibson S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376785/ https://www.ncbi.nlm.nih.gov/pubmed/25816161 http://dx.doi.org/10.1371/journal.pone.0122769 |
Ejemplares similares
-
Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania
por: Juma, Saumu Pazia, et al.
Publicado: (2019) -
Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania
por: Mpagama, Stellah G, et al.
Publicado: (2013) -
Diagnosis and Interim Treatment Outcomes from the First Cohort of Multidrug-Resistant Tuberculosis Patients in Tanzania
por: Mpagama, Stellah G., et al.
Publicado: (2013) -
Evaluation of the Antibody in Lymphocyte Supernatant Assay to Detect Active Tuberculosis
por: Sariko, Margaretha, et al.
Publicado: (2017) -
Gridlock from diagnosis to treatment of multidrug resistant tuberculosis (MDR-TB) in Tanzania: patients’ perspectives from a focus group discussion
por: Mpagama, Stellah G., et al.
Publicado: (2020)